I got the impression that thrombocytopenia will differ with the sequences of the antibody linked to DM1. It could therefore be specific to T-DM1.
thrombocytopenia was observed in 4.7% (7) to 12.9% (6) of patients in phase III studies.
Here's the impt part though: T-DM1 has been generally well tolerated with a lower incidence of grade ≥3 adverse events compared with trastuzumab plus docetaxel (46.4% vs. 90.9%) (5) and lapatinib plus capecitabine (40.8% vs. 57.0%). Other hematologic lineages appear to be relatively unaffected by T-DM1, with low rates of severe anemia, leukopenia, and neutropenia. Some patients do exhibit a slow drift downward in platelet counts with repeated cycles of T-DM1, resembling the pattern induced by cumulative myelosuppression seen with other cytotoxic agents (9). However, even in those patients with a slow downward shift in platelet levels over subsequent cycles,
platelet counts tend to stabilize at a level less severe than grade 3 thrombocytopenia .
Drug-induced thrombocytopenia is relatively common and has been described for hundreds of agents.
However, if compared with Herceptin + Pertuzumab...then it will be another story.
Cynomolgus monkeys dosed with a therapeutic monoclonal antibody (mAbY.1) at ≥50 mg/kg had unexpected acute thrombocytopenia... The hematologic effects made mAbY.1 an unsuitable candidate for further development as a therapeutic agent. This example demonstrates that nonclinical safety studies may be essential for understanding off-target effects of mAbs prior to clinical trials.
Thrombocytopenia, sometimes with other cytopenias, occurs at higher incidence with administration of some therapeutic interferons (IFN), interleukins (IL), and hematopoietic growth factors (e.g., IFNγ, IL-21, IL-3, IL-18, macrophage colony stimulating factor [M-CSF], granulocyte-macrophage colony stimulating factor [GM-CSF.
Which IMGN drug are you guys talking about?
I think they call it profit taking. Sometimes they also call it rotation. I prefer to use the word "manipulation" though.
I was hoping the upward trend will continue until ASH before they start dumping. They'll probably continue dumping until options expiration next week, before they start with a new upward manipulation again until ASH.
Are you invested in any stem cell company for T1D? Which one has the most promising technology of late?
Have you tried the Mannkind dispenser yet? Is it really more convenient or also a pain?
It was just the timing of the release of the ASH abstracts.
It is also ACHN's way of broadcasting to the world that they are experts in structure-based drug design, and they are also able to branch out into other lucrative indications with their in-house expertise.
Amgen, Sanofi, Novartis, Pfizer are desperate to expand their onco pipeline. IMGN will either be snapped up, or will announce new partnerships. SGEN so far has no proof of concept in solid tumors with CLDX trial delay.
Shoot themselves in the foot? You've got the wrong body part there. Seems like Clay and buddies are shooting themselves in the arm or something up their noses.
Too bad I was not able to sell some at this morning's spike.
You've got it wrong there, bud! Ricardo is n SGEN bull, not an SGEN sheep. That bull is probably just busy messing around with a pretty cow with long eyelashes.
Might as well have been Junius. That could explain why SGEN is overpriced and over-valued compared to IMGN. I'm not complaining as I also have SGEN.
I was looking for a chunk of insider buys at that dip, and disappointed to find none. Insiders don't appear to be too bullish on IMGN.
Glad I was able to add low though.
Someone knows that good news will be coming in Dec and they need to push pps down as low as they can so they can load up. I would say that this is a rare buying opportunity for a decent company with sure earnings and earnings potential
Gastric is huge in Japan/Asia.
I bought too soon at 8.36. I have another buy set at 7.11 in case they crash this down. Our Jan 10 options are gone unless at least 1 partnered product deliveries news or new partnership announcement with decent upfront.